Hejing Biotech announced that on November 11, 2025, the company passed a bill to repurchase shares through centralized bidding transactions, with a repurchase amount of 100 million to 200 million yuan for employee shareholding or equity incentives. The repurchase period is until November 11, 2026. As of December 31, 2025, the company had repurchased a total of 904,054 shares, accounting for 0.98% of the total share capital, and a payment capital of 149,955,134.73 yuan. The repurchase price range was 145.59-176.79 yuan/share.

Hejing Biotech announced that on November 11, 2025, the company passed a bill to repurchase shares through centralized bidding transactions, with a repurchase amount of 100 million to 200 million yuan for employee shareholding or equity incentives. The repurchase period is until November 11, 2026. As of December 31, 2025, the company had repurchased a total of 904,054 shares, accounting for 0.98% of the total share capital, and a payment capital of 149,955,134.73 yuan. The repurchase price range was 145.59-176.79 yuan/share.